The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2019 | Acalabrutinib, venetoclax and obinutuzumab upfront for CLL
Matthew Davids, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the preliminary safety and efficacy results from an ongoing open-label, single arm, phase II study (NCT03580928) of acalabrutinib, venetoclax and obinutuzumab (AVO) in patients with previously untreated chronic lymphocytic leukemia (CLL). This trial was MRD-guided and Dr Davids highlights the promising efficacy data for AVO. This drug combination will also be studied against chemoimmunotherapy and acalabrutinib plus venetoclax in the phase 3 trial CL-311 (NCT03836261), which is currently enrolling. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
